Alector (ALEC) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

ALEC · Stock Price

USD 2.44+1.27 (+108.55%)

Market Cap: $244.3M

Historical price data

Market Cap: $244.3MPipeline: 12 drugs (2 Phase 3)Founded: 2013Employees: 100-250HQ: South San Francisco, United States

Sector Ranking#47 in Neuroscience & CNS #76 in Drug Delivery & Formulation

Overview

Alector is a clinical-stage biotech company with a mission to conquer neurodegenerative diseases by modulating the immune system. Its strategy is validated by major partnerships with GSK and AbbVie, and it is advancing a late-stage pipeline led by latozinemab in Phase 3 for frontotemporal dementia. The company's proprietary Alector Brain Carrier (ABC) platform aims to solve the critical challenge of blood-brain barrier delivery, positioning it at the forefront of a novel therapeutic paradigm.

Neurodegenerative DiseasesNeurologyImmunology

Technology Platform

Alector's core platform integrates human genetics for target discovery with antibody engineering for immuno-neurology, supported by the proprietary Alector Brain Carrier (ABC) technology designed to enhance delivery of therapeutics across the blood-brain barrier.

Pipeline

12

12 drugs in pipeline2 in Phase 3

Drug	Indication	Stage
AL001 + Placebo + Open label - AL001	Frontotemporal Dementia	Phase 3
Latozinemab	Neurodegenerative Diseases	Phase 3
GSK4527226	Alzheimer's Disease	Phase 2
AL002 + Placebo	Alzheimer Disease	Phase 2
AL001	Frontotemporal Dementia	Phase 2

Funding History

4

Total raised:$454M

IPO$176MUndisclosedFeb 8, 2019

Series C$205MOrbiMedDec 15, 2017

Series B$32MOrbiMedJun 15, 2015

Series A$41MMRL Ventures FundJan 15, 2014

Opportunities

The primary opportunity is the vast, underserved market for disease-modifying therapies in Alzheimer's and other neurodegenerative diseases.

Success in the ongoing Phase 3 FTD trial could provide rapid regulatory approval in an orphan indication, while validation of the immuno-neurology approach in Alzheimer's would unlock a multi-billion dollar market.

Risk Factors

High clinical failure risk inherent in neurodegenerative disease trials, significant near-term dilution risk given pre-revenue status and low market cap, and intense competition in the Alzheimer's disease space from both established pharma and novel modalities.

Competitive Landscape

Alector faces competition from anti-amyloid and anti-tau therapies in Alzheimer's (e.g., Eisai, Lilly) and a growing field of neuroinflammation targets. Its key differentiation is its genetically-validated, immune-focused approach and first-mover advantage in progranulin elevation for FTD, supported by a proprietary blood-brain barrier delivery platform.